Moderate to Persistent Asthma in the Obese Subject

Stopped early · Phase 4

Conditions studied: Asthma

In brief

Obesity is associated with increased airway inflammation and asthma severity that results in suboptimal control of asthma despite therapy with high dose inhaled corticosteroids (ICS). The investigators suggested that the addition of Singular (montelukast)\[LTRA\] to moderate doses of inhaled corticosteroids will improve asthma control. This cross over study will be treat subjects with moderate dose ICS/LTRA for 12 weeks and high dose ICS with placebo for 12 weeks.

Key facts

Study ID

NCT01016847

Run by

Duke University

People needed

38

Starts

2010-01-01

Expected to finish

2013-11-01

Last updated by the study team

2014-11-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• moderate persistent asthma as defined daily symptoms, nocturnal awakenings >1 time/week but not daily, daily short-acting beta agonist usage
• pre-bronchodilator Force expiratory volume (FEV1)>55% but <90%.
• Subjects must be on controller therapy for asthma with ICS for at least one month prior to enrollment.
• methacholine testing that causes a drop in the FEV1 of 20% (8mg/ml off ICS or 16mg/ml) on ICS within 6 months prior to entry
• physician diagnosis of asthma for at least one year prior to study enrollment.
• Obesity defined as BMI greater than 30.
• subjects must have an Asthma Control Questionnaire (ACQ) score >1.25 on the Juniper Asthma Control Questionnaire (indicating poor asthma control),
• require daily medications for asthma and be compliant with study related medications.

You may not qualify if…

• Subjects must not have been intubated in the last 5 years or unstable asthma symptoms resulting in significant loss or work or school
• upper or lower respiratory tract infection within 1 month of the study
• use of antibiotics within 4 weeks of the study
• use of oral glucocorticoids within 4 weeks
• use of theophylline
• smoking history greater than 10 pack years or any cigarette use within the past two years
• significant non-asthma pulmonary disease or other medical problems
• Subjects planning to undergo gastric bypass surgery within 4 months of the enrollment date will be excluded since weight loss is a potential confounder of asthma control
• Pregnant women will also be excluded

Where it is running

• Duke Asthma Allergy and Airway Center — Durham, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.